Pfizer Inc. (NYSE:PFE) Stake Increased by Strategic Wealth Partners Ltd.

Strategic Wealth Partners Ltd. lifted its stake in Pfizer Inc. (NYSE:PFEGet Rating) by 32.2% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 35,640 shares of the biopharmaceutical company’s stock after acquiring an additional 8,682 shares during the quarter. Strategic Wealth Partners Ltd.’s holdings in Pfizer were worth $1,845,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also modified their holdings of PFE. MAI Capital Management increased its position in Pfizer by 20.5% during the fourth quarter. MAI Capital Management now owns 247,444 shares of the biopharmaceutical company’s stock worth $14,612,000 after buying an additional 42,080 shares during the last quarter. Advisor Resource Council grew its position in shares of Pfizer by 65.5% in the fourth quarter. Advisor Resource Council now owns 57,041 shares of the biopharmaceutical company’s stock valued at $3,369,000 after purchasing an additional 22,572 shares during the last quarter. Ensign Peak Advisors Inc grew its position in shares of Pfizer by 36.1% in the fourth quarter. Ensign Peak Advisors Inc now owns 6,699,905 shares of the biopharmaceutical company’s stock valued at $395,629,000 after purchasing an additional 1,775,904 shares during the last quarter. Members Advisory Group LLC acquired a new stake in shares of Pfizer in the fourth quarter valued at about $211,000. Finally, Garrett Wealth Advisory Group LLC acquired a new stake in shares of Pfizer in the fourth quarter valued at about $238,000. 67.90% of the stock is owned by institutional investors and hedge funds.

Pfizer Stock Performance

NYSE PFE opened at $46.15 on Thursday. The firm has a market cap of $259.01 billion, a price-to-earnings ratio of 9.03, a PEG ratio of 0.59 and a beta of 0.70. The company has a 50 day moving average of $49.41 and a 200-day moving average of $50.46. The company has a current ratio of 1.42, a quick ratio of 1.20 and a debt-to-equity ratio of 0.39. Pfizer Inc. has a 1-year low of $40.94 and a 1-year high of $61.71.

Pfizer (NYSE:PFEGet Rating) last posted its quarterly earnings data on Thursday, July 28th. The biopharmaceutical company reported $2.04 earnings per share for the quarter, topping the consensus estimate of $1.95 by $0.09. The company had revenue of $27.74 billion during the quarter, compared to analyst estimates of $26.20 billion. Pfizer had a net margin of 28.92% and a return on equity of 43.18%. The company’s revenue was up 46.8% on a year-over-year basis. During the same quarter last year, the business posted $1.07 earnings per share. On average, equities analysts forecast that Pfizer Inc. will post 6.54 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 6th. Investors of record on Wednesday, June 29th were issued a $0.40 dividend. This represents a $1.60 dividend on an annualized basis and a dividend yield of 3.47%. The ex-dividend date of this dividend was Thursday, July 28th. Pfizer’s dividend payout ratio is currently 31.31%.

Analysts Set New Price Targets

PFE has been the topic of several research analyst reports. JPMorgan Chase & Co. set a $57.00 price target on Pfizer in a research report on Tuesday, June 28th. The Goldman Sachs Group set a $50.00 price target on Pfizer in a research report on Thursday, September 1st. Morgan Stanley reduced their target price on shares of Pfizer from $52.00 to $49.00 and set an “equal weight” rating for the company in a research note on Friday, July 8th. Berenberg Bank set a $44.00 target price on shares of Pfizer in a research note on Wednesday. Finally, Barclays set a $50.00 target price on shares of Pfizer in a research note on Thursday, September 1st. Nine research analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Pfizer currently has a consensus rating of “Moderate Buy” and an average target price of $57.00.

Pfizer Company Profile

(Get Rating)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.

Featured Articles

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFEGet Rating).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.